The global antiepileptic drugs market is anticipated to grow at a considerable CAGR of 2.6% during the forecast period. The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers and acquisitions, geographical expansion, new product launch, and product innovation to remain competitive in the marketplace. For instance, Therachon Holding AG, a privately owned clinical-stage biotechnology business, has been acquired by pfizer Inc.
Therachon Holding AG is a privately held clinical-stage biotechnology company. Pfizer Inc. paid an additional USD 470 million for Therachon Holding AG, in addition to $340 million, under the terms of the acquisition. Following the fulfilment of major milestones in the marketing and development of TA-46, a further payment of USD 470 million was made. In September 2019, GW Pharmaceuticals plc. launches the new innovations drugs, EPIDYOLEX that are used for the Dravet syndrome or Lennox Gastaut syndrome as an adjunction the therapy of seizures.
In addition, in May 2021, Epilepsy Foundation, a U.S. based non-profit national foundation entered into a collaboration with Eisai Inc. is a Japanese pharmaceutical company that developed the Epilepsy Digital Experience Navigator platform designed to empower people with epilepsy. The caregiver and clinician use data to better improvement of the epilepsy journey. Further, in November 2019, SK Biopharmaceuticals, Co., Ltd., a global pharmaceutical company focused on developing and bringing treatments to market for central nervous system (CNS) disorders, announced that the U.S. Food and Drug Administration (FDA) has approved XCOPRI (cenobamate tablets) as a treatment for partial-onset seizures in adults. With the approval of XCOPRI, clinicians will have a new treatment option for patients who are still having focal (partial-onset) seizures. The approval is based on the findings of two global, randomised, double-blind, placebo-controlled studies, as well as a major, global, multi-center, open-label safety study that involved adults with uncontrolled partial-onset seizures who were using one to three anti-epileptic drugs concurrently (AEDs).
To Request a Sample of our Report on Antiepileptic Drugs Market: https://www.omrglobal.com/request-sample/antiepileptic-drugs-market
Market Coverage
- The market number available for – 2022-2030
- Base year- 2022
- Forecast period- 2022-2030
Segment Covered-
- By Drug Type
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– including Abbott Laboratories, GlaxoSmithKline plc, Pfizer Inc., and others.
Antiepileptic Drugs Market Report Segment
By Drug Type
- First Generation AEDs
- Phenytoin (Dilantin, Phenytek)
- Carbamazepine (Carbatrol)
- Oxycarbazepine (Trileptal)
- Valproate (Depakote)
- Others
- Second Generation AEDs
- Lamotrigine (Lamictal)
- Pregabalin (Lyrica)
- Rufinamide (Banzel/Inovelon)
- Levetiracetam (Keppra)
- Others
A full Report of Antiepileptic Drugs Market is Available @ https://www.omrglobal.com/industry-reports/antiepileptic-drugs-market
Antiepileptic Drugs Market Report Segment by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Company Profiles
- Abbott Laboratories
- Cephalon, Inc.
- Eisai Co.
- GlaxoSmithKline plc
- GW Pharmaceuticals Inc.
- Lundbeck A/S
- Johnson & Johnson
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Sunovion Pharmaceuticals Inc.
- Takeda Pharmaceutical Co. Ltd.
- UCB S.A.
- Valeany Pharmaceuticals International Inc.
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
